UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety
- PMID: 37470120
- DOI: 10.2217/pgs-2023-0096
UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety
Abstract
Tweetable abstract Pretreatment UGT1A1 genotyping and a 70% irinotecan dose intensity in poor metabolizers is safe, feasible, cost-effective and essential for safe irinotecan treatment in cancer patients. It is time to update guidelines to swiftly enable the implementation of UGT1A1 genotype-guided irinotecan dosing in routine oncology care.
Keywords: PGx; UGT1A1; irinotecan; personalized medicine; pharmacogenetics; pharmacogenomics; precision dosing; pretreatment.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical